Atsena to Advance Pivotal Trial for X-Linked Retinoschisis
An independent data monitoring review of Parts A and B of Atsena Therapeutics’ LIGHTHOUSE study found ATSN-201 safe and...
EU Clinical Trials Face Cost, Speed, and China Competition Pressure
At the Clinical Trial Innovation Summit 2025 in Basel, industry leaders from UCB, Novo Nordisk, Novartis, and Medable debated...
How LLMs Can Audit LSD Clinical Trial Ratings in Real Time
MindMed is running three phase three trials of pharmaceutically optimized LSD with a two-person AI team and a custom...
AI Platform Predicts Clinical Trial Outcomes with High Accuracy
At the Clinical Trial Innovation Summit 2025 in Basel, QuantHealth's Chief Medical Officer presented AI-driven trial simulation technology capable...
Novartis Restructures Clinical Ops to Scale Trial Innovation Beyond Pilots
Novartis built a dedicated Global Clinical Operations Innovation Team 18 months ago to move past one-off pilots and embed...
MST Matches ECT Efficacy—and Leaves Memory Intact. The CREST-MST Trial Just Changed the Convulsive Therapy Conversation
The CREST-MST trial in Lancet Psychiatry shows magnetic seizure therapy matches ECT remission rates in TRD with a superior...
The ICU Trial That Should Embarrass Every Sponsor Hiding Behind “Ethical Complexity”
A JAMA RCT on ICU restraint strategies just proved rigorous trial design works even in critically ill patients —...
Ascentage Pharma Presents Promising Cancer Research at AACR
Across four AACR posters, Ascentage reported preclinical synergy signals spanning hematologic and solid tumors: olverembatinib enhanced chemotherapy activity in...
Sutro’s Emerging ADC Pipeline Shows Promising Preclinical Data
In preclinical studies presented at AACR, Sutro’s tissue factor–targeted ADC STRO-004 delivered broad antitumor control across multiple TF-expressing solid...
ALXN1840’s Triumph: Neurologic Hope in Wilson Disease
Clinically meaningful neurologic worsening at Week 48 occurred in 25% of patients on standard of care versus 9% on...